Evidence map›Paper›PMID 35740021›Full record

ArticleAntioxidants (Basel, Switzerland)2022

Enhanced Oxidative DNA-Damage in Peritoneal Dialysis Patients via the TXNIP/TRX Axis.

Tina Oberacker, Peter Fritz, Moritz Schanz, Mark Dominik Alscher, Markus Ketteler, Severin Schricker

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Hesperidin ameliorates HJournal of animal science and biotechnology · 2024
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tina OberackerDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376 Stuttgart, Germany.ORCID 0000-0002-8887-1198
Peter FritzDepartment of General Internal Medicine and Nephrology, Robert-Bosch-Hospital, Auerbachstr. 110, 70376 Stuttgart, Germany.
Moritz SchanzDepartment of General Internal Medicine and Nephrology, Robert-Bosch-Hospital, Auerbachstr. 110, 70376 Stuttgart, Germany.
Mark Dominik AlscherDepartment of General Internal Medicine and Nephrology, Robert-Bosch-Hospital, Auerbachstr. 110, 70376 Stuttgart, Germany.
Markus KettelerDepartment of General Internal Medicine and Nephrology, Robert-Bosch-Hospital, Auerbachstr. 110, 70376 Stuttgart, Germany.
Severin SchrickerDepartment of General Internal Medicine and Nephrology, Robert-Bosch-Hospital, Auerbachstr. 110, 70376 Stuttgart, Germany.
Robert Bosch Hospital · DEDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DE

Funding

Berthold Leibinger Stiftung PDRobert-Bosch-Stiftung s
6 · The paper itself

Abstract

Peritoneal dialysis (PD) is an effective method of renal replacement therapy, providing a high level of patient autonomy. Nevertheless, the long-term use of PD is limited due to deleterious effects of PD fluids to the structure and function of the peritoneal membrane leading to loss of dialysis efficacy. PD patients show excessive oxidative stress compared to controls or chronic kidney disease (CKD) patients not on dialysis. Therefore, defense systems against detrimental events play a pivotal role in the integrity of the peritoneal membrane. The thioredoxin-interacting-protein (TXNIP)/thioredoxin (TRX) system also plays a major role in maintaining the redox homeostasis. We hypothesized that the upregulation of TXNIP negatively influences TRX activity, resulting in enhanced oxidative DNA-damage in PD patients. Therefore, we collected plasma samples and human peritoneal biopsies of healthy controls and PD patients as well. Using ELISA-analysis and immunohistochemistry, we showed that PD patients had elevated TXNIP levels compared to healthy controls. Furthermore, we demonstrated that PD patients had a reduced TRX activity, thereby leading to increased oxidative DNA-damage. Hence, targeting the TXNIP/TRX system as well as the use of oxidative stress scavengers could become promising therapeutic approaches potentially applicable in clinical practice in order to sustain and improve peritoneal membrane function.

Indexed as

oxidative damageoxidative stressperitoneal dialysisthioredoxinthioredoxin-interacting-protein

Identifiers

PMID35740021
PMCPMC9220040
OpenAlexW4281977232

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.